Technology News and Research

RSS

San Antonio Methodist Hospital upgrades to Leksell Gamma Knife Perfexion system

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that it has entered into a contract to supply a Leksell Gamma Knife® PerfexionTM system to Methodist Hospital in San Antonio, Texas. This new Perfexion system, the eighth placed by AMS to date, will replace an existing Gamma Knife supplied by AMS and is expected to begin treating patients later this year.

5 Feb 2010

iPSC technology for identifying agents that reprogram human somatic cells receives Notice of Allowance

Fate Therapeutics, Inc. received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application Number 10/997,146 entitled "Methods for Reprogramming Somatic Cells." Upon issuance, the patent will cover foundational induced pluripotent stem cell (iPSC) technology for identifying agents that enable the reprogramming of human somatic cells, including pluripotency genes, small molecules and biologics.

5 Feb 2010

BioClinica signs three-year, multi-million dollar deal with Cephalon

BioClinica, Inc., a leading global provider of clinical trial services, has signed a three-year, multi-million dollar deal with Cephalon, Inc. for clinical trial technology and support services.

From Clario 5 Feb 2010

ARMC selects HMS to provide hospital information system applications for its general acute hospital

Arizona Regional Medical Center (ARMC) has selected Healthcare Management Systems, Inc.® (HMS) to provide hospital information system applications for its general acute hospital, located in Mesa, Ariz.

5 Feb 2010

Bioheart initiates REGEN Phase I Clinical Trial for testing genetically modified MyoCell in CHF patients

Bioheart, Inc., announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart’s MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells,that are grown from a patient’s own muscle. MyoCell® has been tested successfully on patients in four clinical trials.

5 Feb 2010

Scientists discover new technique to destroy individual diseased cells

Using lasers and nanoparticles, scientists at Rice University have discovered a new technique for singling out individual diseased cells and destroying them with tiny explosions.

5 Feb 2010

ThermoGenesis announces distribution agreement with GE Healthcare for its AXP System

ThermoGenesis Corp., a leading supplier of innovative products for processing and storing adult stem cells, today announced a new enhanced distribution agreement with GE Healthcare, a unit of General Electric Company, for its AXP® AutoXpress ™ (AXP) System used in the processing of cord blood.

5 Feb 2010

St. Jude Medical receives European approval for Fortify ST ICD and Unify CRT-D defibrillators

St. Jude Medical, Inc. today announced European CE Mark approval and first implants of its Fortify™ and Fortify ST implantable cardioverter defibrillators (ICD) and Unify™ cardiac resynchronization therapy defibrillator (CRT-D). The devices will be fully launched in Europe later this spring, and U.S. versions of the Fortify ICD and Unify CRT-D are expected to be launched later this year. The reduced size of these new devices compared to those of previous generations creates the smallest available device footprint in the industry.

5 Feb 2010

Sequenom CMM launches SensiGene Fetal RHD Genotyping test for pregnant RhD negative women

Sequenom, Inc. today announced the launch of the SensiGene™ Fetal RHD Genotyping test by Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM).

5 Feb 2010

Arrayit's VIP DNA testing technology receives patent protection in Israel

Arrayit Corporation, a life sciences and healthcare technology leader, announced today that the Company has received patent protection in the State of Israel for its proprietary Variation Identification Platform™ (VIP™) DNA testing technology. The Israeli patent extends Arrayit's current patent portfolio, which includes VIP patents in the United States, Singapore, New Zealand, China, South Korea, and the European Union.

5 Feb 2010

PSKW & Associates purchases Triax Media

PSKW & Associates LLC of Edison, New Jersey, which owns the Loyalty Rx Co-pay Card, has purchased Triax Media LLC of Irvine, California. At the same time, PSKW has licensed the purchase to its subsidiary, Centricity Group LLC of Mendham, New Jersey.

5 Feb 2010

FDA approves first laser treatment for stretch marks

Palomar Medical Technologies, Inc. is pleased to announce that the Lux1540™ Fractional non-ablative laser handpiece has received the first clearance by the United States Food and Drug Administration (FDA) for the treatment of striae (stretch marks) using a fractional laser. This new clearance will allow aesthetic practitioners to treat the millions of women worldwide who have unwanted stretch marks.

4 Feb 2010

Allergan acquires Serica Technologies

Morningside Technology Ventures, Prism VentureWorks, and Ivy Capital Partners are pleased to announce the acquisition of their portfolio company, Serica Technologies, Inc. by Allergan, Inc. Serica is a growth-stage medical device company focused on the development of biodegradable silk-based scaffolds for use in tissue regeneration in numerous therapeutic areas. Following the acquisition, Serica became a wholly owned subsidiary of Allergan.

4 Feb 2010

IMRIS to acquire NASL

IMRIS Inc. today announced that it has entered into a definitive agreement to acquire NeuroArm Surgical Limited ("NASL"), a privately held company based in Calgary, Alberta, and its magnetic resonance-compatible neurosurgical robot. The companies expect to close the transaction no later than February 8, 2010, subject to the satisfaction of customary closing conditions. IMRIS has also entered into a memorandum of understanding with MacDonald Dettwiler and Associates Limited ("MDA") to create the next generation of the technology.

4 Feb 2010

Data analysis of Delcath Systems' Phase III trial of melphalan to be commenced

Delcath Systems, Inc., a medical technology company testing its proprietary treatment system for metastatic cancers to the liver, announced today that sufficient events have been reached to allow data analysis to begin on its Phase III trial. The trial uses the drug melphalan to treat patients with metastatic melanoma in the liver.

4 Feb 2010

Mike Critelli introduces Allviant’s CarePass technology at CHVI event

Dossia Chairman Mike Critelli, a recognized innovator in health benefits and workforce wellness, introduced Allviant Corporation’s CarePass™ technology at the Center for Health Value Innovation (CHVI) event on February 2 in Washington, D.C.

4 Feb 2010

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

Alkermes, Inc. today announced that it has developed a novel, proprietary LinkeRx™ technology platform to enable the creation of injectable extended-release versions of antipsychotics and other central nervous system (CNS) therapies.

4 Feb 2010

Phase Forward to participate in DIA Workshop and Clinical Trial Supply event

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, will participate in two industry events this month: The 13th Annual DIA Workshop in Japan for Clinical Data Management (Booths 4 and 5) and VIB Pharma’s 11th Annual Clinical Trial Supply (Booth 3).

4 Feb 2010

Flexpoint Sensor Systems focuses on smaller contracts and production orders

Flexpoint Sensor Systems, Inc. http://www.flexpoint.com announced that the Company has modified the business model. In addition to focusing on large contracts in the medical bed and automotive industry, the company is more aggressively focusing on smaller contracts and production orders that produce immediate income for the Company.

4 Feb 2010

CTD seeks small molecule drug discovery and therapeutic antibody targets from academic researchers

A major centre created by the Medical Research Council (MRC) and MRC Technology (MRCT) in order to fast-track the discovery and development of novel drugs, opens its first call for targets today.

4 Feb 2010

Technology News and Research

San Antonio Methodist Hospital upgrades to Leksell Gamma Knife Perfexion system

iPSC technology for identifying agents that reprogram human somatic cells receives Notice of Allowance

BioClinica signs three-year, multi-million dollar deal with Cephalon

ARMC selects HMS to provide hospital information system applications for its general acute hospital

Bioheart initiates REGEN Phase I Clinical Trial for testing genetically modified MyoCell in CHF patients

Scientists discover new technique to destroy individual diseased cells

ThermoGenesis announces distribution agreement with GE Healthcare for its AXP System

St. Jude Medical receives European approval for Fortify ST ICD and Unify CRT-D defibrillators

Sequenom CMM launches SensiGene Fetal RHD Genotyping test for pregnant RhD negative women

Arrayit's VIP DNA testing technology receives patent protection in Israel

PSKW & Associates purchases Triax Media

FDA approves first laser treatment for stretch marks

Allergan acquires Serica Technologies

IMRIS to acquire NASL

Data analysis of Delcath Systems' Phase III trial of melphalan to be commenced

Mike Critelli introduces Allviant’s CarePass technology at CHVI event

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

Phase Forward to participate in DIA Workshop and Clinical Trial Supply event

Flexpoint Sensor Systems focuses on smaller contracts and production orders

CTD seeks small molecule drug discovery and therapeutic antibody targets from academic researchers

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News